BioXcel Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BTAI Nasdaq 8731 https://www.bioxceltherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioXcel Therapeutics Inc

BTAI: Important Data Readouts in 2Q23… - Mar 22nd, 2023 12:21 pm
OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering - Mar 14th, 2023 8:15 pm
BioXcel Therapeutics, Inc. (NASDAQ:BTAI): When Will It Breakeven? - Mar 11th, 2023 2:25 pm
Q4 2022 BioXcel Therapeutics Inc Earnings Call - Mar 10th, 2023 7:32 am
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights - Mar 9th, 2023 12:00 pm
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023 - Feb 23rd, 2023 12:00 pm
BioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell Today - Feb 21st, 2023 12:00 pm
BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype - Feb 14th, 2023 2:50 pm
BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium - Feb 13th, 2023 10:00 pm
Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023 - Feb 8th, 2023 7:27 pm
BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer - Feb 8th, 2023 12:00 pm
BTAI: Multiple Catalysts Ahead in 2023 - Jan 27th, 2023 12:00 pm
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer - Jan 11th, 2023 12:00 pm
A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy - Dec 27th, 2022 12:34 pm
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference - Dec 22nd, 2022 12:00 pm
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease - Dec 19th, 2022 12:00 pm
Why BioXCel Therapeutics Stock Jumped This Week - Dec 15th, 2022 9:45 pm
2 Beaten-Down Stocks to Watch Closely Next Year - Dec 6th, 2022 2:53 pm
Why BioXcel Therapeutics Stock Triumphed This Week - Dec 2nd, 2022 11:02 pm
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference - Dec 1st, 2022 12:00 pm